Beclometasone/formoterol

DRUG2 trials

Sponsors

University of Dundee, Chiesi Farmaceutici S.p.A.

Conditions

Chronic Obstructive Pulmonary Disease

Phase 3

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD

CompletedNCT01917331

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2014-03-31End: 2016-03-31Updated: 2021-10-29

Phase 4

Beta Blocker Therapy in Moderate to Severe COPD

CompletedNCT01656005

University of DundeeChronic Obstructive Pulmonary Disease

Start: 2012-08-31End: 2016-07-31Updated: 2019-04-23

Related Papers

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.

2020-06-0510 citations

<p>Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA</p>

International Journal of COPD2019-02-0121 citations

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β<sub>2</sub>-Agonist Therapy: An Integrated Post Hoc Analysis.

2018-09-0612 citations

P277 Bisoprolol blunts domiciliary fev1 in copd patients taking concomitant dual or triple inhaler therapy

2017-11-15

Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD

2017-09-011 citations

Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD

QJM2017-07-2114 citations

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.

2016-09-01280 citations